1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. COMPASS THERAPEUTICS INC
Compass Therapeutics Inc
XNAS: CMPX
Download real time
0.880.00(0.00%)
New 52W Low in past week
444.2K
XNAS Volume

XNAS 15 Oct, 2026 10:06 AM (EDT)

Portfolio

Alert

My Notes

Compass Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Compass Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Compass Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Compass Therapeutics Inc Jun-2026 Quarterly Net Profit is $-25 Million which is growth of -26.5% YoY.

Compass Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
0.9
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
2720.31815.821.11816.612.215.912.815.411.913.3
Operating Profit
-27-20.3-18-15.8-21.1-18-16.6-12.2-15-12.8-15.4-11.9-13.3
⌄
1.8-2.31.61.2-1.61.82-222.1
Profit Before Tax
-25.2-18.3-15.7-14.3-19.9-16.6-15-10.5-13.1-10.8-13.4-10-11.3
Tax
-------
⌄
-25.2-18.3-15.7-14.3-19.9-16.6-15-10.5-13.1-10.8-13.4-10-11.3
Diluted NI Avail to Com Stockholders Ann.
-25.2-18.3-15.7-14.3-19.9-16.6-15-10.5-13.1-10.8-13.4-10-11.3
Basic EPS
-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1
Diluted EPS After ExtraOrdinary
-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1
Number Of Shares End
186.8186.4185.1168.8138.3138.2137.8137.6137.6136.6127.6127.4126.7
Net Income Continuing Discontinued Operations
-25.2-18.3-15.7-14.3-19.9-16.6-15-10.5-13.1-10.8-13.4-10-11.3
Normalized Income
-20.3-13.2-13.9-13-17.1-14.1-12.8-8.3-11-8.8-11.8-8.3-9.7
Interest Income
1.8-2.31.61.2-1.61.82-222.1
Interest
-------------
Net Interest Income
1.8-2.31.61.2-1.61.82-222.1
EBIT
-27-18.3-18-15.8-21.1-16.6-16.6-12.2-15-10.8-15.4-11.9-13.3
EBITDA
-26.6-18-17.7-15.5-20.7-16.3-16.3-11.8-14.6-10.3-14.9-11.5-12.9
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.40.40.40.40.40.40.40.50.50.50.50.50.5
Profit From Continuing Operations
-25.2-18.3-15.7-14.3-19.9-16.6-15-10.5-13.1-10.8-13.4-10-11.3
Normalized EBITDA
-26.6-19.9-17.6-15.5-20.7-17.6-16.2-11.8-14.6-12.3-14.9-11.5-12.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Compass Therapeutics Inc competitor comparison and performance snapshot within industry

Compass Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Compass Therapeutics Inc Annual Revenue is $0 Million which is growth of -100.0% YoY.

  • NEGATIVE

    Annual Net Profit Compass Therapeutics Inc Annual Net Profit is $-66 Million which is growth of -34.7% YoY.

Compass Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
-
-
 0.9
Cost Of Rev. Ann.
-
-
 --------
Gross Profit Ann.
-
-
 --------
Operating Exp. Ann.
20.4%
21.2%
81.172.857.550.441.731.327.834.138.3
Operating Profit Ann.
-
-
-81.1-72.8-56.6-50.4-41.7-31.3-27.8-34.1-38.3
⌄
38.7%
-
 6.47.37.92.4-0.3-0.8-0.5-0.1
Other Exp. Ann.
-
-
 -0.1-0.1-0.1-50.6-0.8-0.10.2
PBT Ann.
-
-
-73.4-66.5-49.4-42.5-39.2-82.2-29.5-34.7-38.2
Tax Ann.
-
-
 -00.10.1
⌄
-
-
-73.4-66.5-49.4-42.5-39.2-82.2-29.5-34.7-38.3
Diluted NI Avail to Com Stockholders Ann.
-
-
-73.4-66.5-49.4-42.5-39.2-82.2-29.5-34.7-38.3
EPS Ann.
-
-
 -0.4-0.4-0.3-0.4-1.3-0.6-0.7-0.7
Diluted EPS Ann.
-
-
 -0.4-0.4-0.3-0.4-1.3-0.6-0.7-0.7
Number Of Shares End
16.2%
28.9%
 185.1137.8127.6117.986.552.152.1-
Total Exp. Ann.
20.4%
21.2%
 72.857.550.441.731.327.834.138.3
Net Income Continuing Discontinued Operations Ann.
-
-
-73.4-66.5-49.4-42.5-39.2-82.2-29.5-34.7-38.3
Normalized Income Ann.
-
-
-60.5-58.1-40.8-36.4-3423-26-34-38
Interest Income Ann.
38.7%
129.7%
 6.47.37.92.400.10.70.7
Interest Ann.
-
-
 ---0.40.91.20.8
EBITDA Ann.
-
-
-77.7-72.6-56.1-48.5-39.7-80.2-26.2-32.1-36.2
Reconciled Cost Of Rev. Ann.
-
-
 --------
Reconciled Depr. Ann.
-7.6%
-9%
1.51.51.81.91.91.62.42.11.9
Profit From Continuing Operations Ann.
-
-
-73.4-66.5-49.4-42.5-39.2-82.2-29.5-34.7-38.3
Normalized EBITDA Ann.
-
-
-79.6-71.4-54.9-48.5-37.4-29.6-25.3-31.2-35.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
26.6%
2Y CAGR
20.2%
3Y CAGR
20.4%
5Y CAGR
21.2%
7Y CAGR
9.6%
Operating Expenses Annual Cr growth is higher than historical averages.

Compass Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Compass Therapeutics Inc Dec-2025 Total Shareholders Fund is $197 Million which is growth of 57.1% YoY.

  • POSITIVE

    Total Assets Compass Therapeutics Inc Dec-2025 Total Assets is $220 Million which is growth of 56.4% YoY.

Compass Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
3.2%
33.4%
219.6140.4156.9199.6153.851.930.464.6
⌄
8.2%
13.7%
22.815.28.31813.712149149.4
⌄
2.7%
37.6%
196.8125.2148.5181.6140.139.9-118.6-84.8
Total Capitalization Ann.
2.7%
36.3%
196.8125.2148.5181.6140.141.8-109.3-73.7
Tangible Assets Ann.
2.7%
37.6%
196.8125.2148.5181.6140.139.9-118.6-84.8
Working Capital Ann.
3.1%
37.3%
195.9123.9146.1178.6136.540.116.450.4
Invested Capital Ann.
2.7%
31.9%
196.8125.2148.5181.6140.149.3-103.7-70
Tangible Book Value Ann.
2.7%
37.5%
196.8125.2148.5181.6140.140-118.6-84.8
Borrowings Ann.
50.1%
1.1%
9.86.61.72.949.314.914.8
Net Debt Ann.
-
-
--------
Share Issued Ann.
12.2%
27.9%
178.3137.8127.7126.3101.352.161.161.1
Number Of Shares End
16.2%
28.9%
185.1137.8127.6117.986.552.152.1-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
56.4%
2Y CAGR
18.3%
3Y CAGR
3.2%
5Y CAGR
33.4%
7Y CAGR
19.1%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
57.3%
2Y CAGR
34%
3Y CAGR
-4.7%
5Y CAGR
6.7%
7Y CAGR
7.4%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
57.2%
2Y CAGR
15.1%
3Y CAGR
2.7%
5Y CAGR
37.6%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Compass Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Compass Therapeutics Inc Book Value Per Share is $1 which is growth of 28.5% YoY.

  • NEUTRAL

    ROE Compass Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Compass Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
RoA Ann. %
-
-
--33.22%-23.84%-22.20%-79.92%-71.70%-73.14%-59.24%
ROE Ann. %
-
-
--36.07%-25.74%-24.38%-91.30%---
ROIC %
-
-
--12-9.9-8.5-14.7-15.3--
OPM Ann. %
-
-
--6,661.76%------
Inventory Turnover Ratio Ann.
-
-
--------
Asset Turnover Ann. %
-
-
-0------
Working Capital Turnover Ann.
-
-
0
Quick Ratio Ann.
-
-
-14.319.511.513.64.72.66.8
Current Ratio Ann.
-
-
-1519.712.113.852.77
Interest Coverage Ratio Ann.
-
-
-----221.1-31.5-27.2-48.8
LT Debt To Equity Ann.
-
-
-0.1000.1--
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Compass Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Compass Therapeutics Inc Cash From Operating Activity is $-49 Million which is growth of -9.6% YoY.

  • NEGATIVE

    Net Cash Flow Compass Therapeutics Inc Net Cash Flow is $-13 Million which is growth of -166.7% YoY.

Compass Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18
⌄
-
-
-49.1-44.9-40.6-34.1-19.7-26.8-31.7-33.7
⌄
-
-
-93.346.827-151.2-1.80-0.5-2
⌄
19.6%
21.7%
129.617.32.975.8118.648.564
Cash Plus Cash Eqv. End Of Year Ann.
-3.8%
-8%
31.243.524.235144.547.325.657.8
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-12.819.3-10.7-109.697.221.8-32.228.3
Cash Plus Cash Eqv. Begin Of Year Ann.
-32.7%
11.5%
44.124.235144.547.325.657.829.4
Income Tax Paid Supplemental Data Ann.
-
-
--------
Interest Paid Supplemental Data Ann.
-
-
---0.40.91.10.6
Capex Ann.
-
-
-0-0-0-0.2-1.6-0.1-0.5-2
Issuance Of Capital Stock Ann.
21.9%
17.9%
13818.13.176.2128.360.549.2
Issuance Of Debt Ann.
-
-
------15
Repayment Of Debt Ann.
-
-
----9.4-5.6--
Repurchase Of Capital Stock Ann.
-
-
--------
Free Cash Flow Ann.
-
-
-49.2-44.9-40.7-34.3-21.2-26.9-32.2-35.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
649.1%
2Y CAGR
568.5%
3Y CAGR
19.6%
5Y CAGR
21.7%
7Y CAGR
10.6%
Cash from Financing Annual Activity growth is higher than historical averages.
×